Objectives: The alkylphospholipid oleylphosphocholine (OlPC) is a structural analogue of miltefosine and may represent a potential therapeutic backup for the treatment of visceral leishmaniasis (VL). This laboratory study compared the in vitro and in vivo activity profile of both OlPC and miltefosine.
Introduction
The neglected tropical parasitic disease leishmaniasis is prevalent in 88 countries spread over four continents 1 and is most frequent among the most vulnerable poorer populations of East Africa, the Indian subcontinent and South America. 2 Among the different clinical forms [visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL)], the visceral form caused by Leishmania donovani has by far the greatest impact, not only because of lethality if left untreated, 3 but also because of the growing incidence of resistance against the first-line antimony (Sb) drugs in high-endemic regions. 4, 5 In an attempt to counter this evolution, the Kala-azar elimination programme that was officially launched in India and Nepal in 2008 6 advocates the use of the alkylphosphocholine miltefosine as a first-line alternative to Sb. The alkylphosphocholines are a class of molecules derived from alkylglycerophosphocholines and alkyllysolecithins, which were originally developed as anticancer drugs. 7, 8 After demonstration of in vitro and in vivo antileishmania potential in laboratory models of several alkylphosphocholine derivatives, 9, 10 hexadecyl-phosphocholine or miltefosine was chosen for further development and subsequently recognized as a ground-breaking novel oral therapy for leishmaniasis. 11 Miltefosine is currently registered in India, 12 # The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2012; 67: 2707 -2712 doi:10.1093/jac/dks273 Advance Access publication 10 July 2012
Germany and Colombia. Although miltefosine is highly effective, its side effects, narrow therapeutic window and teratogenicity limit its widespread use. 13, 14 In addition, its very long plasma elimination half-life 15, 16 may ultimately favour parasite selection towards drug resistance. Rescue is now being sought in the use of drug combinations. 17 Obviously there is need for additional treatment options that are effective, safe, easy to administer and amenable to combination therapy. This laboratory study builds on the therapeutic significance of miltefosine and covers the profiling of the alkylphosphocholine analogue oleylphosphocholine (OlPC) (Figure 1 ) to verify its possible incremental value for the treatment of leishmaniasis. OlPC was evaluated in vitro against different Leishmania species and in vivo for its efficacy and tolerability in an early curative model of VL in the hamster.
Materials and methods
Culture media, reagents and products NaHCO 3 , potato starch, Giemsa stain and paromomycin sulphate were purchased from Sigma-Aldrich (Bornem, Belgium). RPMI 1640 medium, PBS, L-glutamine and fetal calf serum (FCS) were supplied by Invitrogen (Merelbeke, Belgium). Miltefosine and pentavalent antimony (Sb V ) (sodium stibogluconate) were kindly provided by WHO-TDR (Geneva, Switzerland). A stock solution of Sb V was prepared in PBS at 378C immediately before use. A commercial formulation of amphotericin B (Fungizonew, Bristol-Myers Squibb) was used. Crystalline OlPC was supplied by Dafra Pharma International (Turnhout, Belgium). Miltefosine and OlPC stock solutions were prepared in water and stored at room temperature in the dark for a maximum of 7 days. Besides a simple aqueous formulation of crystalline substance that is used to make tablets (OlPC/H 2 O), OlPC was also formulated as nanoliposomal suspension in phosphate-buffered sucrose at pH 7.5 (OlPC liposomes). The liposomes consisted of OlPC, cholesterol (Solvay Pharmaceuticals, Switzerland) and oleic acid (Hana Corporation, Korea) in a molar ratio of 41.51: 42.42: 5.13. The liposomes were produced by a cross-flow injection technique (Polymun Scientific, Austria) at a concentration of 18 mg/mL. OlPC liposomes showed a mean diameter of 75 nm as measured by dynamic light-scattering analysis with a Malvern Nano ZS particle sizer (Malvern Instruments Ltd, UK). The formulation was sterile-filtrated and stored at 4 -88C until use. If needed for experimentations, it was further diluted in PBS. . The strains were maintained as previously described. 18 For the in vivo experiments, the drug-sensitive laboratory strain of L. infantum (MHOM/MA(BE)/67) was used. 19 In vitro drug susceptibility assay Amastigotes derived from the spleen of donor RAG1.B6 or BALB/c mice were used to infect primary peritoneal mouse macrophages collected 2 days after intraperitoneal induction with 2 mL 2% soluble starch. 20 The cells were grown in 16-well tissue culture slides (Lab Tecw) in RPMI 1640 medium supplemented with 200 mM L-glutamine, 16.5 mM NaHCO 3 and 10% FCS at 378C and 5% CO 2 . An aliquot of 100 mL of RPMI 1640 medium containing 4×10 5 /mL peritoneal macrophages was added to each well and left for 24 h. Then 100 mL of amastigotes were added at a ratio of seven amastigotes to one macrophage. After 24 h, serial dilutions of the antileishmania drugs were added (30 mg/mL as highest concentration) and incubated for 5 days (including replacement with fresh drug-containing medium after 72 h). Parasite growth was microscopically assessed after methanol fixation and staining with a 10% Giemsa solution. The results are expressed as the percentage reduction in parasite burdens compared with untreated control wells and the 50% inhibitory concentration (IC 50 ) was calculated (Statvieww V5.0, SAS Inc.). All experiments were performed at least twice in duplicate.
Leishmania species/strains

Early curative hamster model of VL
Female golden hamsters were purchased from Janvier (France) and kept in quarantine for at least 1 week before starting the experiment. Food for laboratory rodents and drinking water were available ad libitum. The animals were randomly allocated to the different experimental groups (six to eight per group) based on their body weight. At the start of the experiment (day 0) they were infected intracardially under fluothane inhalation anaesthesia with 2×10 7 amastigotes of L. infantum obtained from the spleen of a heavily infected donor hamster. At day 21 the animals received oral treatment by gavage and were monitored for adverse or clinical effects until the end of the experiment. In the first experiment, aqueous and liposomal OlPC and miltefosine were dosed at 20 and 40 mg/kg (equivalent to 49.1 and 98.2 mmol/kg, respectively) by oral gavage for 5 consecutive days. In the second experiment, animals were dosed at 20, 10 or 5 mg/kg for 5 consecutive days or at 100, 50 or 25 mg/kg as a single dose. All animals were weighed twice weekly during the course of the experiment to monitor their general health status. On day 35 the amastigote burdens in the liver, spleen and bone marrow were determined. The liver and spleen of the individual animals were weighed (except bone marrow); impression smears were fixed in methanol and stained with Giemsa for microscopic enumeration Fortin et al.
of the number of amastigotes per cell by counting a minimum of 500 nuclei. The results are expressed as Leishman Donovan units (LDU; the mean number of amastigotes per nucleus×mg organ weight). The percentage reduction as compared with the vehicle-treated infected control animals was used as a measure of drug efficacy. 21 Non-infected controls were not included.
The animal experiments were carried out following the recommendations of EC Directive 2010/63/EU. The Ethics Committee of the University of Antwerp (UA-ECD 2010-017-18-8-2010) approved the study protocol. Each hamster experiment was carried out only once with one dosing group common to both experiments. The established reproducibility of our laboratory model and the large number of animals (six to eight) in each experimental group made additional independent replicates less necessary.
Results
The in vitro efficacy of OlPC against the intracellular amastigotes of different Old World and New World Leishmania spp. was compared with that of miltefosine and the other currently available antileishmanial drugs (amphotericin B, paromomycin and Sb V ). OlPC showed a similar in vitro efficacy profile as miltefosine, with IC 50 values in the low micromolar range (,5 mM, except for L. major and L. braziliensis) ( Table 1) .
The early curative in vivo efficacy of OlPC against L. infantum was evaluated in the hamster. Two formulations of OlPC (aqueous solution and liposomal) were dose titrated in direct comparison with miltefosine. The treatment was started at day 21 post-infection. Both OlPC and miltefosine were administered either as a multiple-dose regimen of five oral doses or as a single-dose regimen. The parameter for efficacy was the amastigote reduction in the liver, spleen and bone marrow on day 35 post-infection compared with vehicle-treated control animals.
The first experiment (Table 2) , in which the animals were dosed at 20 or 40 mg/kg for 5 days, showed that both OlPC formulations were equipotent with a markedly higher efficacy compared with miltefosine. At 20 mg/kg, 0%, 60.7% and 38.7% reductions in amastigote burdens were obtained in liver, spleen and bone marrow, respectively, of miltefosine-treated animals, compared with 71.4%, 98.7% and 93.5% for OlPC liposomes and 91.0%, 99.4% and 98.1% for OlPC/H 2 O. At 40 mg/kg, OlPC treatment resulted in .99% parasite elimination in all target organs regardless of the formulation. As for miltefosine, the administration of 40 mg/kg resulted in a 99.2% reduction in spleen, 95.5% in bone marrow and only 65.4% in liver. All the drugs were well tolerated, with an average weight loss of about 2% and 6% in the miltefosine-and OlPC/H 2 O-treated groups, respectively. This weight loss can be partly attributed to the daily handling of the animals, although no weight loss was recorded in the animals receiving the OlPC liposomal formulation (Table S1 , available as Supplementary data at JAC Online).
The second experiment (Table 2 ) compared a single dose and a 5 day dosing regimen for OlPC/H 2 O for the total doses of 25, 50 and 100 mg/kg. The single administrations of OlPC/H 2 O and of OlPC liposomes were also compared for efficacy and tolerability. Treatment with OlPC/H 2 O for 5 consecutive days at 20 mg/kg reduced the parasite burden by 97.6%, 99.9% and 97.6% in liver, spleen and bone marrow, respectively. These findings confirm the results of the first experiment. At 5×10 and 5×5 mg/kg, the efficacy gradually decreased to 56.0% and 25.4% reduction in liver, 75.8% and 47.4% in spleen, and 55.7% and 2.7% in bone marrow, demonstrating the distinct dosedependent effect. Interestingly, the administration of the same total dose as a single administration resulted in about comparable levels of efficacy as when the total dose was given over 5 days, with a marginally better result for OlPC liposomes. Specifically, single dosing at 100 mg/kg of OlPC/H 2 O and OlPC liposomes reduced parasite burdens by 96.2% and 99.3% in liver, 99.8% and 99.9% in spleen, and 87.6% and 96.9% in bone marrow, respectively. At 50 mg/kg, the efficacy slightly dropped but remained comparable for both formulations with 62.5% and 69.4% parasite burden reductions in the liver, and 94.0% and 88.7% in the spleen. No relevant activity (,60%) was maintained after a single dose at 25 mg/kg. Both OlPC formulations, even after a single administration as high as 100 mg/kg, were well tolerated based on the absence of adverse side effects and the unaffected evolution of the body weight throughout In vitro and in vivo activity of oleylphosphocholine against Leishmania infantum the experiments (Table S1 , available as Supplementary data at JAC Online).
Discussion
Shortly after the introduction of miltefosine on the market, a proposed research agenda was put forward to explore the full potential of this novel oral drug and ascertain its long-term use. 22 One of the main recommendations included the evaluation against other Leishmania species to define its full clinical use spectrum with particular reference to HIV-co-infected patients. Another important issue was the likelihood of the rapid development of drug resistance, specifically in anthroponotic VL 23 and related to the particularly long elimination halflife.
16 Surprisingly, the possible need for backup compounds was not highlighted and may have been inspired by the fact that miltefosine itself was already a spin-off of a former anticancer programme, 13, 24 hence requiring minimal development efforts and costs for leishmaniasis as a neglected disease. 25 In retrospect, and now being able to assess the considerable added therapeutic value of miltefosine, the present study specifically explored the comparative in vitro and in vivo efficacy of miltefosine and its close analogue OlPC (Figure 1 ) to define whether OlPC could represent a valid backup candidate. Miltefosine was found not to be the most active compound of its class against Leishmania parasites in vitro 24 and a direct comparison of the efficacy between miltefosine and OlPC against Entamoeba histolytica 26 revealed that the alkyl chain length and the presence of non-saturation had a considerable impact on the potency. Here, OlPC showed the highest activity among the whole series of analogues (IC 50 of 15 mM for OlPC compared with 53 mM for miltefosine). Our in vitro results on Leishmania spp. do not highlight such a difference, but show a comparable potency between OlPC and miltefosine, with a marginal exception for L. major and L. braziliensis (Table 1) . The early curative VL hamster model with L. infantum clearly revealed that OlPC is more potent compared with miltefosine after multiple or single oral dosing ( Table 2 ). The dose titration of OlPC/H 2 O and OlPC liposomes at 100, 50 and 25 mg/kg proved that the lowest active total dose was 50 mg/kg. An almost complete cure can be achieved with a total dose of 200 mg/kg. The fact that similar parasite suppression levels were observed when OlPC was administered as a single dose or as multiple daily doses may suggest that the overall bioavailability may be far more important for parasite killing than the peak plasma concentrations. Interestingly, a single administration of 100 mg/kg was sufficient to reduce the parasite load in the three target organs-liver, spleen and bone marrow-by more than 95%. This result suggests that OlPC has the potential to be administered under a shorter regimen compared with miltefosine, which is currently a 28 day dosing regimen. 27 Obviously this would represent a practical advantage in terms of compliance and effectiveness over the currently available treatments.
The use of liposomal formulations to lower the toxicity has been linked to a modified pharmacokinetic behaviour 28 in combination with an enhanced macrophage targeting potential. Female hamsters were infected with 2×10 7 L. infantum amastigotes on day 0 and treated with the test compounds on day 21. Amastigote burdens in the liver, spleen and bone marrow were determined 10 days after the last treatment (day 35). The percentage reduction as compared with the vehicle-treated infected control animals (VIC) is used as a measure for drug activity. a A reduction of at least 80% is considered as the cut-off for relevant efficacy.
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This strategy has been exploited for amphotericin B (Ambisomew), which maintains its first-line status in the treatment of leishmaniasis. 3 The oral administration of liposomes is still controversial due to the potential degradation of the liposomal structure in the digestive tract. Our observations do not suggest a different systemic bioavailability compared with the aqueous form, since both OlPC formulations showed similar efficacy and tolerance (at least following a 5 day treatment). Pilot pharmacokinetic data in dogs after oral dosing at 1 mg/kg have indicated a comparable bioavailability of both formulations (83%), a rather slow absorption (T max 4 -8 h for OlPC/H 2 O and 4 h for OlPC liposomes; C max 2990 for OlPC/H 2 O and 3340 ng/mL for OlPC liposomes) and a plasma elimination half-life of 59.5 h for OlPC/H 2 O and 61.2 h for OlPC liposomes (A. Fortin, unpublished data). Compared with the published data on miltefosine in rats 13 and humans, 16 OlPC appears to clear more rapidly, which may be beneficial with regard to the selection potential for resistance. Quite recently the first case of miltefosine resistance in a clinical field isolate of L. infantum was documented. 30 The potential differential properties of the liposomes compared with the aqueous form of OlPC await proper pharmacokinetic evaluation and/or longer treatment duration. In terms of efficacy, further studies are needed to assess the clinical performance in a chronic infection model using a late curative therapeutic approach and adopting a longer post-treatment evaluation period to assess the potential of full parasitological cure, particularly after single dosing. The present study points out that OlPC can be considered as a potential backup drug for miltefosine, but still requires a lot of pre-clinical and clinical investigations.
